Compare Gilead Sciences, Inc. (GILD) vs SPDR Gold Trust (GLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs SPDR Gold Trust — how do they compare? Gilead Sciences, Inc. trades at $135.96 (market cap $168.35B), while SPDR Gold Trust trades at $404.79. The key difference: Gilead Sciences, Inc. pays a 2.42% dividend while SPDR Gold Trust pays none. Which is the better fit depends on your goals.
| GILD | GLD | |
|---|---|---|
Market Cap | $168.35B | — |
Sector | Health | — |
52-Week High | $155.80 | $495.90 |
52-Week Low | $110.56 | $305.27 |
Enterprise Value | $191.42B | — |
Dividend Yield | 2.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $136.73, up 2.76% on the day, with a bullish technical signal and strong analyst consensus. Recent Q2 2026 earnings beat revenue estimates despite a net loss driven by acquisition costs, while HIV drug sales and raised guidance provide fundamental support. The stock is near its pivot point of $136, with resistance at $137 and support at $134.
Outlook remains positive given robust HIV franchise growth and pipeline advancements, but risks include patent cliffs, high debt, and profitability volatility. With 67% of analysts rating it a Buy and a consensus price target of $151.22, the stock offers potential upside, though investors must weigh execution risks against growth catalysts.
GLD trades at $403.80, up 0.29% with bullish technical signals from moving averages and strong momentum indicators. The ETF benefits from recent inflation data showing cooling CPI pressures and heightened geopolitical tensions driving safe-haven demand. Recent news highlights gold's resilience amid Federal Reserve policy uncertainty and strong central bank buying activity.
Outlook remains positive with technical resistance at $405-$407 and support at $399-$401. Key risks include potential Fed policy shifts and dollar strength, while catalysts include sustained inflation concerns and geopolitical instability. The ETF's momentum suggests potential for further gains toward resistance levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About SPDR Gold Trust
GLD is the largest physically backed gold ETF in the world. It offers investors a cost-efficient and secure way to track the price of gold bullion without the need for physical storage.
Read more on GLD →
